Ivabradine: pre-clinical and clinical evidence in the setting of ventricular arrhythmias

Area of Science:

• Cardiology
• Electrophysiology
• Pharmacology

Background:

• Ivabradine selectively inhibits the sinoatrial node's funny current (If), reducing heart rate.
• Current guidelines recommend ivabradine for heart failure and chronic coronary syndromes with angina.
• Its role in ventricular arrhythmias is an emerging area of research.

Purpose of the Study:

• To review the existing evidence on ivabradine's role in ventricular arrhythmias.
• To evaluate its efficacy in various experimental and clinical settings.
• To identify areas requiring further research, particularly randomized clinical trials.

Main Methods:

• Review of experimental studies on acute myocardial ischemia, reperfusion, digitalis-induced arrhythmias, and CPVT.
• Analysis of clinical studies investigating ivabradine's impact on premature ventricular contractions and arrhythmia burden.
• Assessment of data regarding ivabradine's effect in myocardial ischemia.

Main Results:

• Experimental studies suggest promising results for ivabradine in various arrhythmia models.
• Clinical data indicate a beneficial role in reducing premature ventricular contractions in dilated cardiomyopathy and arrhythmias in CPVT.
• No beneficial effect of ivabradine was observed in reducing ventricular arrhythmias during myocardial ischemia.

Conclusions:

• Ivabradine demonstrates potential benefits in specific ventricular arrhythmia contexts.
• Further randomized clinical trials are essential to fully elucidate its role.
• The current evidence suggests a need for more research to establish definitive clinical guidelines for ivabradine in arrhythmia management.